OpenLegislation

Division E CONTROL TESTS ON THE FINISHED PRODUCT

United Kingdom

Original text. Later amendments are not shown.

For all tests, the description of the techniques for analysing the finished product shall be set out in sufficiently precise detail for quality assessment.

The dossier shall include particulars relating to control tests on the finished product. Where appropriate monographs exist, if test procedures and limits other than those mentioned in the monographs of the European Pharmacopoeia, or failing this, in the pharmacopoeia of a Member State, are used, proof must be supplied that the finished product would, if tested in accordance with those monographs, meet the quality requirements of that pharmacopoeia for the pharmaceutical form concerned. The application for marketing authorisation shall list those tests, which are carried out on representative samples of each batch of finished product. The frequency of the tests, which are not carried out on each batch, shall be stated. Release limits shall be indicated.

Where available, chemical and biological reference material of the European Pharmacopoeia shall be used. If other reference preparations and standards are used, they shall be identified and described in detail.

  1. 1General characteristics of the finished product
  2. 2Identification of active substance(s)
  3. 3Batch titre or potency
  4. 4Identification and assay of adjuvants
  5. 5Identification and assay of excipient components
  6. 6Safety tests
  7. 7Sterility and purity test
  8. 8Residual humidity
  9. 9Inactivation

Notes on Annex II

Footnotes

f1

This Annex will be amended by the Commission in accordance with Articles 146 and 153. All references to Articles or to ‘this Directive’ in this Annex, unless otherwise specified, are to be understood as references to Directive 2001/82/EC.